|
Jun 19
|
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
|
|
Jun 19
|
Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
|
|
Jun 18
|
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
|
|
Jun 18
|
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
Jun 18
|
One AstraZeneca Insider Raised Stake By 50% In Previous Year
|
|
Jun 17
|
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
|
|
Jun 17
|
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
|
|
Jun 17
|
AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
|
|
Jun 17
|
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
|
|
Jun 17
|
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
|
|
Jun 17
|
AstraZeneca reports positive data from Phase III mantle cell lymphoma trial
|
|
Jun 17
|
AstraZeneca/Fibrogen’s Roxadustat FDA Review Further Delayed Following Unanticipated Advisory Committee Request
|
|
Jun 16
|
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
|
|
Jun 14
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 14
|
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
|
Jun 13
|
AstraZeneca CFO: 'We've come a long way in our oncology portfolio'
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 13
|
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
|
Jun 13
|
FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
|